Leo Egbujiobi, MD
Cardiovascular Disease · Beloit, WINPI 1972679355
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 32.6% of the total. Reporting peaked in 2022 at $2,613 and has fallen 87.6% since, to $324 in 2025.
Across 211 payments — averaging $42.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- Johnson & Johnson$693
- Boston Scientific$660
- Novartis$589
- E.r. Squibb & Sons, L.L.C.$247
- plus $2K from 21 others
What the payments were for
- Travel & lodging$4,08746%
- Food & beverage$4,82554%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $2,919 |
| Abbott | 15 | $2,074 |
| Johnson & Johnson | 23 | $693 |
| Boston Scientific | 11 | $660 |
| Novartis | 24 | $589 |
| E.r. Squibb & Sons, L.L.C. | 17 | $247 |
| Pfizer | 23 | $213 |
| Daiichi Sankyo Inc. | 4 | $202 |
| AstraZeneca | 10 | $186 |
| Silk Road Medical, Inc. | 1 | $181 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $172 |
| Amgen | 10 | $162 |
| Sanofi-aventis U.S. LLC | 10 | $143 |
| Lundbeck LLC | 7 | $86 |
| Novo Nordisk | 4 | $81 |
| Edwards Lifesciences | 1 | $60 |
| Boehringer Ingelheim | 4 | $60 |
| Baxter Healthcare | 2 | $43 |
| Livanova USA, Inc. | 1 | $39 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 2 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Gilead | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,960 in reported general payments places this provider in the 85th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 833 | $902,582 |
| XareltoRivaroxaban | 200 | $225,373 |
| EntrestoSacubitril/Valsartan | 138 | $200,165 |
| Repatha SureclickEvolocumab | 117 | $157,701 |
| BrilintaTicagrelor | 66 | $60,123 |
| Praluent PenAlirocumab | 24 | $24,818 |
| Ranolazine ErRanolazine | 209 | $20,825 |
| Repatha SyringeEvolocumab | 30 | $20,196 |
| JardianceEmpagliflozin | 14 | $15,673 |
| Metoprolol Succinate | 1,028 | $14,367 |
| Isosorbide Dinitrate | 245 | $11,776 |
| ClopidogrelClopidogrel Bisulfate | 929 | $9,731 |
| Nitroglycerin PatchNitroglycerin | 146 | $9,223 |
| Atorvastatin Calcium | 1,025 | $8,734 |
| Warfarin Sodium | 885 | $7,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $213 | $902,582833 claims |
| Johnson & JohnsonXarelto | $693 | $225,373200 claims |
| NovartisEntresto | $589 | $200,165138 claims |
| AstraZenecaBrilinta, Farxiga | $186 | $66,08178 claims |
| Boehringer IngelheimJardiance | $60 | $15,67314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Beloit
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Tadeo Diaz BalderramaFond du Lac$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.